Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors

Molecular Pharmaceutics

Volumn 12, Issue 11, 2015, Pages 3924-3934

  Tomaszowski, Karl Heinz ^a   Schirrmacher, Ralf ^b   Kaina, Bernd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

ABC transporter; DNA repair; drug targeting; inhibitors; MGMT

Indexed keywords

6 O BENZYLGUANINE; ABC TRANSPORTER; ALKYLATING AGENT; BREAST CANCER RESISTANCE PROTEIN; DNA METHYLTRANSFERASE INHIBITOR; GLUCOSE; LOMEGUATRIB; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE INHIBITOR; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; ENZYME INHIBITOR; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ACTIVE TRANSPORT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CHEMOSENSITIZATION; CONJUGATE; CONTROLLED STUDY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; TIME-DEPENDENT INHIBITION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG RESISTANCE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CELL PROLIFERATION; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; GLUCOSE; HUMANS; NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84946434473     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00341     Document Type: Article

References (65)

1. Kufe, D. W., Pollock, R. E., Weichselbaum, R. R., Bast, R. C., Jr., Gansler, T. S., Holland, J. F., Frei, E., III, Eds. Cancer Medicine, 6th ed.; B.C. Decker: Hamilton, ON, Canada, 2003.
2. Fu, D.; Calvo, J. A.; Samson, L. D. Balancing repair and tolerance of DNA damage caused by alkylating agents Nat. Rev. Cancer 2012, 12, 104-20 10.1038/nrc3185
3. Kaina, B.; Christmann, M.; Naumann, S.; Roos, W. P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents DNA Repair 2007, 6 (8) 1079-99 10.1016/j.dnarep.2007.03.008
4. Quiros, S.; Roos, W. P.; Kaina, B. Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles Cell Cycle 2010, 9 (1) 168-78 10.4161/cc.9.1.10363
5. Loveless, A. Possible relevance of O-6 alkylation of deoxyguanosine to the mutagenicity and carcinogenicity of nitrosamines and nitrosamides Nature 1969, 223 (5202) 206-7 10.1038/223206a0
6. Toorchen, D.; Topal, M. D. Mechanisms of chemical mutagenesis and carcinogenesis: effects on DNA replication of methylation at the O6-guanine position of dGTP Carcinogenesis 1983, 4 (12) 1591-7 10.1093/carcin/4.12.1591
7. Mojas, N.; Lopes, M.; Jiricny, J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA Genes Dev. 2007, 21 (24) 3342-55 10.1101/gad.455407
8. Ochs, K.; Kaina, B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent Cancer Res. 2000, 60 (20) 5815-24
9. Margison, G. P.; Santibanez Koref, M. F.; Povey, A. C. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine Mutagenesis 2002, 17 (6) 483-7 10.1093/mutage/17.6.483
10. Tong, W. P.; Kirk, M. C.; Ludlum, D. B. Formation of the cross-link 1-[N3-deoxycytidyl),2-[N1-deoxyguanosinyl]ethane in DNA treated with N,N′-bis(2-chloroethyl)-N-nitrosourea Cancer Res. 1982, 42 (8) 3102-5
11. Nikolova, T.; Hennekes, F.; Bhatti, A.; Kaina, B. Chloroethylnitrosourea-induced cell death and genotoxicity: cell cycle dependence and the role of DNA double-strand breaks, HR and NHEJ Cell Cycle 2012, 11 (14) 2606-19 10.4161/cc.20862
12. Pegg, A. E. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools Chem. Res. Toxicol. 2011, 24 (5) 618-39 10.1021/tx200031q
13. Gerson, S. L. MGMT: its role in cancer aetiology and cancer therapeutics Nat. Rev. Cancer 2004, 4 (4) 296-307 10.1038/nrc1319
14. Thomas, A. D.; Jenkins, G. J.; Kaina, B.; Bodger, O. G.; Tomaszowski, K. H.; Lewis, P. D.; Doak, S. H.; Johnson, G. E. Influence of DNA repair on nonlinear dose-responses for mutation Toxicol. Sci. 2013, 132 (1) 87-95 10.1093/toxsci/kfs341
15. Fahrer, J.; Kaina, B. O6-methylguanine-DNA methyltransferase in the defense against N-nitroso compounds and colorectal cancer Carcinogenesis 2013, 34 (11) 2435-42 10.1093/carcin/bgt275
16. Verbeek, B.; Southgate, T. D.; Gilham, D. E.; Margison, G. P. O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy Br. Med. Bull. 2008, 85, 17-33 10.1093/bmb/ldm036
17. Kaina, B.; Margison, G. P.; Christmann, M. Targeting O(6)-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy Cell. Mol. Life Sci. 2010, 67 (21) 3663-81 10.1007/s00018-010-0491-7
18. Koch, D.; Hundsberger, T.; Boor, S.; Kaina, B. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma J. Neuro-Oncol. 2007, 82 (1) 85-9 10.1007/s11060-006-9244-8
19. Javanmard, S.; Loktionova, N. A.; Fang, Q.; Pauly, G. T.; Pegg, A. E.; Moschel, R. C. Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2′-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine J. Med. Chem. 2007, 50 (21) 5193-201 10.1021/jm0705859
20. Penketh, P. G.; Shyam, K.; Baumann, R. P.; Ishiguro, K.; Patridge, E. V.; Zhu, R.; Sartorelli, A. C. A strategy for selective O(6)-alkylguanine-DNA alkyltransferase depletion under hypoxic conditions Chem. Biol. Drug Des. 2012, 80 (2) 279-90 10.1111/j.1747-0285.2012.01401.x
21. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters Nature Reviews Cancer 2002, 2 (1) 48-58 10.1038/nrc706
22. Dean, M.; Rzhetsky, A.; Allikmets, R. The human ATP-binding cassette (ABC) transporter superfamily Genome Res. 2001, 11 (7) 1156-66 10.1101/gr.GR-1649R
23. Deeley, R. G.; Westlake, C.; Cole, S. P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins Physiol. Rev. 2006, 86 (3) 849-99 10.1152/physrev.00035.2005
24. Ambudkar, S. V.; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P-glycoprotein: from genomics to mechanism Oncogene 2003, 22 (47) 7468-85 10.1038/sj.onc.1206948
25. Munoz, M.; Henderson, M.; Haber, M.; Norris, M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer IUBMB Life 2007, 59 (12) 752-7 10.1080/15216540701736285
26. Robey, R. W.; Polgar, O.; Deeken, J.; To, K. W.; Bates, S. E. ABCG2: determining its relevance in clinical drug resistance Cancer Metastasis Rev. 2007, 26 (1) 39-57 10.1007/s10555-007-9042-6
27. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer Nat. Rev. Drug Discovery 2006, 5 (3) 219-34 10.1038/nrd1984
28. Kaina, B.; Muhlhausen, U.; Piee-Staffa, A.; Christmann, M.; Garcia Boy, R.; Rosch, F.; Schirrmacher, R. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death J. Pharmacol. Exp. Ther. 2004, 311 (2) 585-93 10.1124/jpet.104.071316
29. Muhlhausen, U.; Schirrmacher, R.; Piel, M.; Lecher, B.; Briegert, M.; Piee-Staffa, A.; Kaina, B.; Rosch, F. Synthesis of 131I-labeled glucose-conjugated inhibitors of O6-methylguanine-DNA methyltransferase (MGMT) and comparison with nonconjugated inhibitors as potential tools for in vivo MGMT imaging J. Med. Chem. 2006, 49 (1) 263-72 10.1021/jm050588q
30. Preuss, I.; Eberhagen, I.; Haas, S.; Eibl, R. H.; Kaufmann, M.; von Minckwitz, G.; Kaina, B. O6-methylguanine-DNA methyltransferase activity in breast and brain tumors Int. J. Cancer 1995, 61 (3) 321-6 10.1002/ijc.2910610308
31. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 1976, 72, 248-54 10.1016/0003-2697(76)90527-3
32. Roos, W. P.; Binder, A.; Bohm, L. Determination of the initial DNA damage and residual DNA damage remaining after 12 h of repair in eleven cell lines at low doses of irradiation Int. J. Radiat. Biol. 2000, 76 (11) 1493-500 10.1080/09553000050176252
33. Renart, J.; Reiser, J.; Stark, G. R. Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: a method for studying antibody specificity and antigen structure Proc. Natl. Acad. Sci. U. S. A. 1979, 76 (7) 3116-20 10.1073/pnas.76.7.3116
34. Hollo, Z.; Homolya, L.; Davis, C. W.; Sarkadi, B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter Biochim. Biophys. Acta, Biomembr. 1994, 1191 (2) 384-8 10.1016/0005-2736(94)90190-2
35. Homolya, L.; Hollo, Z.; Germann, U. A.; Pastan, I.; Gottesman, M. M.; Sarkadi, B. Fluorescent cellular indicators are extruded by the multidrug resistance protein J. Biol. Chem. 1993, 26 (29) 21493-6
36. Christmann, M.; Verbeek, B.; Roos, W. P.; Kaina, B. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry Biochim. Biophys. Acta, Rev. Cancer 2011, 1816 (2) 179-90 10.1016/j.bbcan.2011.06.002
37. Roos, W. P.; Kaina, B. DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis Cancer Lett. 2013, 332 (2) 237-48 10.1016/j.canlet.2012.01.007
38. Roos, W. P.; Jost, E.; Belohlavek, C.; Nagel, G.; Fritz, G.; Kaina, B. Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-beta and valproic acid Cancer Res. 2011, 71 (12) 4150-60 10.1158/0008-5472.CAN-10-3498
39. Wiewrodt, D.; Nagel, G.; Dreimuller, N.; Hundsberger, T.; Perneczky, A.; Kaina, B. MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome Int. J. Cancer 2008, 122 (6) 1391-9 10.1002/ijc.23219
40. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. Rational use of in vitro P-glycoprotein assays in drug discovery J. Pharmacol. Exp. Ther. 2001, 299 (2) 620-8
41. Lebedeva, I. V.; Pande, P.; Patton, W. F. Sensitive and specific fluorescent probes for functional analysis of the three major types of mammalian ABC transporters PLoS One 2011, 6 (7) e22429 10.1371/journal.pone.0022429
42. Petriz, J.; Garcia-Lopez, J. Flow cytometric analysis of P-glycoprotein function using rhodamine 123 Leukemia 1997, 11 (7) 1124-30 10.1038/sj.leu.2400659
43. Laupeze, B.; Amiot, L.; Courtois, A.; Vernhet, L.; Drenou, B.; Fauchet, R.; Fardel, O. Use of the anionic dye carboxy-2′,7′-dichlorofluorescein for sensitive flow cytometric detection of multidrug resistance-associated protein activity Int. J. Oncol. 1999, 15 (3) 571-6 10.3892/ijo.15.3.571
44. Robey, R. W.; Steadman, K.; Polgar, O.; Morisaki, K.; Blayney, M.; Mistry, P.; Bates, S. E. Pheophorbide a is a specific probe for ABCG2 function and inhibition Cancer Res. 2004, 64 (4) 1242-6 10.1158/0008-5472.CAN-03-3298
45. Choi, C. H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal Cancer Cell Int. 2005, 5, 30 10.1186/1475-2867-5-30
46. Saengkhae, C.; Loetchutinat, C.; Garnier-Suillerot, A. Kinetic analysis of rhodamines efflux mediated by the multidrug resistance protein (MRP1) Biophys. J. 2003, 85 (3) 2006-14 10.1016/S0006-3495(03)74628-1
47. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T.; McArthur, G. A.; Group, B.-S. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 2011, 364 (26) 2507-16 10.1056/NEJMoa1103782
48. Hodi, F. S.; O'Day, S. J.; McDermott, D. F.; Weber, R. W.; Sosman, J. A.; Haanen, J. B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J. C.; Akerley, W.; van den Eertwegh, A. J.; Lutzky, J.; Lorigan, P.; Vaubel, J. M.; Linette, G. P.; Hogg, D.; Ottensmeier, C. H.; Lebbe, C.; Peschel, C.; Quirt, I.; Clark, J. I.; Wolchok, J. D.; Weber, J. S.; Tian, J.; Yellin, M. J.; Nichol, G. M.; Hoos, A.; Urba, W. J. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 2010, 363 (8) 711-23 10.1056/NEJMoa1003466
49. Kaina, B.; Christmann, M. DNA repair in resistance to alkylating anticancer drugs Int. J. Clin. Pharmacol. Ther. 2002, 40 (8) 354-67 10.5414/CPP40354
50. Hegi, M. E.; Diserens, A. C.; Gorlia, T.; Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.; Hainfellner, J. A.; Mason, W.; Mariani, L.; Bromberg, J. E.; Hau, P.; Mirimanoff, R. O.; Cairncross, J. G.; Janzer, R. C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma N. Engl. J. Med. 2005, 352 (10) 997-1003 10.1056/NEJMoa043331
51. Christmann, M.; Nagel, G.; Horn, S.; Krahn, U.; Wiewrodt, D.; Sommer, C.; Kaina, B. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma Int. J. Cancer 2010, 127 (9) 2106-18 10.1002/ijc.25229
52. Weller, M.; Stupp, R.; Reifenberger, G.; Brandes, A. A.; van den Bent, M. J.; Wick, W.; Hegi, M. E. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol. 2010, 6 (1) 39-51 10.1038/nrneurol.2009.197
53. Quinn, J. A.; Jiang, S. X.; Reardon, D. A.; Desjardins, A.; Vredenburgh, J. J.; Rich, J. N.; Gururangan, S.; Friedman, A. H.; Bigner, D. D.; Sampson, J. H.; McLendon, R. E.; Herndon, J. E., 2nd; Walker, A.; Friedman, H. S. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma J. Clin. Oncol. 2009, 27 (8) 1262-7 10.1200/JCO.2008.18.8417
54. Ranson, M.; Hersey, P.; Thompson, D.; Beith, J.; McArthur, G. A.; Haydon, A.; Davis, I. D.; Kefford, R. F.; Mortimer, P.; Harris, P. A.; Baka, S.; Seebaran, A.; Sabharwal, A.; Watson, A. J.; Margison, G. P.; Middleton, M. R. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma J. Clin. Oncol. 2007, 25 (18) 2540-5 10.1200/JCO.2007.10.8217
55. Altenberg, B.; Greulich, K. O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes Genomics 2004, 84 (6) 1014-20 10.1016/j.ygeno.2004.08.010
56. Reinhard, J.; Eichhorn, U.; Wiessler, M.; Kaina, B. Inactivation of O(6)-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors Int. J. Cancer 2001, 93 (3) 373-9 10.1002/ijc.1336
57. Litman, T.; Druley, T. E.; Stein, W. D.; Bates, S. E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance Cell. Mol. Life Sci. 2001, 58 (7) 931-59 10.1007/PL00000912
58. Takano, M.; Yumoto, R.; Murakami, T. Expression and function of efflux drug transporters in the intestine Pharmacol. Ther. 2006, 109 (1-2) 137-61 10.1016/j.pharmthera.2005.06.005
59. Coulter, R.; Blandino, M.; Tomlinson, J. M.; Pauly, G. T.; Krajewska, M.; Moschel, R. C.; Peterson, L. A.; Pegg, A. E.; Spratt, T. E. Differences in the rate of repair of O6-alkylguanines in different sequence contexts by O6-alkylguanine-DNA alkyltransferase Chem. Res. Toxicol. 2007, 20 (12) 1966-71 10.1021/tx700271j
60. Pauly, G. T.; Hughes, S. H.; Moschel, R. C. Comparison of mutagenesis by O6-methyl- and O6-ethylguanine and O4-methylthymine in Escherichia coli using double-stranded and gapped plasmids Carcinogenesis 1998, 19 (3) 457-61 10.1093/carcin/19.3.457
61. Dolan, M. E.; Chae, M. Y.; Pegg, A. E.; Mullen, J. H.; Friedman, H. S.; Moschel, R. C. Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase Cancer Res. 1994, 54 (19) 5123-30
62. Ranson, M.; Middleton, M. R.; Bridgewater, J.; Lee, S. M.; Dawson, M.; Jowle, D.; Halbert, G.; Waller, S.; McGrath, H.; Gumbrell, L.; McElhinney, R. S.; Donnelly, D.; McMurry, T. B.; Margison, G. P. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors Clin. Cancer Res. 2006, 12 (5) 1577-84 10.1158/1078-0432.CCR-05-2198
63. Watson, A. J.; Sabharwal, A.; Thorncroft, M.; McGown, G.; Kerr, R.; Bojanic, S.; Soonawalla, Z.; King, A.; Miller, A.; Waller, S.; Leung, H.; Margison, G. P.; Middleton, M. R. Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib Clin. Cancer Res. 2010, 16 (2) 743-9 10.1158/1078-0432.CCR-09-1389
64. Dolan, M. E.; Posner, M.; Karrison, T.; Radosta, J.; Steinberg, G.; Bertucci, D.; Vujasin, L.; Ratain, M. J. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors Clin. Cancer Res. 2002, 8 (8) 2519-23
65. Raaijmakers, M. H. ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia Leukemia 2007, 21 (10) 2094-102 10.1038/sj.leu.2404859